These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3012625)

  • 1. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689).
    Rasey JS; Krohn KA; Grunbaum Z; Spence AM; Menard TW; Wade RA
    Radiat Res; 1986 Jun; 106(3):366-79. PubMed ID: 3012625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913).
    Rasey JS; Grunbaum Z; Krohn KA; Menard TW; Spence AM
    Radiat Res; 1985 Apr; 102(1):130-7. PubMed ID: 2984715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.
    Rasey JS; Krohn KA; Magee S; Nelson N; Chin L
    Radiat Res; 1986 Nov; 108(2):167-75. PubMed ID: 3024202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
    Utley JF; Marlowe C; Waddell WJ
    Radiat Res; 1976 Nov; 68(2):284-91. PubMed ID: 185642
    [No Abstract]   [Full Text] [Related]  

  • 5. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
    Rasey JS; Nelson NJ; Mahler P; Anderson K; Krohn KA; Menard T
    Radiat Res; 1984 Mar; 97(3):598-607. PubMed ID: 6328565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo dephosphorylation of WR-2721 monitored by 31P NMR spectroscopy.
    Knizner SA; Jacobs AJ; Lyon RC; Swenberg CE
    J Pharmacol Exp Ther; 1986 Jan; 236(1):37-40. PubMed ID: 3001292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Yuhas JM
    Cancer Res; 1980 May; 40(5):1519-24. PubMed ID: 6245795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.
    Milas L; Hunter N; Reid BO; Thames HD
    Cancer Res; 1982 May; 42(5):1888-97. PubMed ID: 6279288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors.
    Rasey JS; Krohn KA; Menard TW; Spence AM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1487-90. PubMed ID: 3019965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological effects of the radiation protector WR-151327 in mice.
    van Beek ME; Doak RL; Sigdestad CP; Grdina DJ
    Radiat Res; 1990 Oct; 124(1):79-84. PubMed ID: 2236499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
    Milas L; Ito H; Hunter N
    Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
    Milas L; McBride WH; Hunter N; Ito H
    Cancer Res; 1984 Jun; 44(6):2382-6. PubMed ID: 6327014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
    Utley JF; Seaver N; Newton GL; Fahey RC
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins.
    Livesey JC; Grunbaum Z; Krohn KA
    Biochem Pharmacol; 1990 Jun; 39(11):1807-12. PubMed ID: 2160821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in normal tissue responsiveness to WR-2721.
    Yuhas JM; Afzal SM; Afzal V
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1537-9. PubMed ID: 6090357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of [3H]-3-hydroxykynurenine in mice.
    Watanabe M; Sugimori Y
    Cancer Res; 1976 Feb; 36(2 Pt 1):309-12. PubMed ID: 1260739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of WR-2721 in normal and malignant tissues of mice and rats bearing solid tumors: dependence on tumor type, drug dose and species.
    Washburn LC; Carlton JE; Hayes RL
    Radiat Res; 1974 Aug; 59(2):475-83. PubMed ID: 4371539
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
    Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
    J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of tissue oxidation-reduction state with carbon-13 nuclear magnetic resonance spectroscopy.
    Livesey JC; Golden RN; Shankland EG; Grunbaum Z; Richards TL; Wade RA; Krohn KA
    Cancer Res; 1989 Apr; 49(8):1937-40. PubMed ID: 2539249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the radioprotective effects of topical applications of MEA, WR-2721, and N-acetylcysteine on murine skin.
    Verhey LJ; Sedlacek R
    Radiat Res; 1983 Jan; 93(1):175-83. PubMed ID: 6296910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.